NYSE:MDTMedical Equipment
Medtronic Evolut TAVR Trial Win May Recast Growth And Risk Profile
Medtronic (NYSE:MDT) reported that its Evolut transcatheter aortic valve achieved superior clinical outcomes compared with Edwards's Sapien valve in a large head to head TAVR trial.
The three year study showed better haemodynamic performance and lower thrombosis rates for Evolut, including in patients with small annuli.
The findings point to a potential shift in TAVR market share and could influence physician choice and future regulatory and hospital adoption.
For a company like Medtronic,...